SPSiddhartha Pulukuri

Siddhartha Pulukuri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siddhartha Pulukuri has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure S1 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    Supplementary Figure S1. Targeting CD73 sensitizes quasi-mesenchymal tumors to anti-CTLA4 immune checkpoint blockade therapy

  • Open Access

    Supplementary Figure S4 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    Supplementary Figure S4. Presence of CD4+ T-cell helper subsets in responders and non-responders.

  • Open Access

    Figure 6 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    EMP regulates CD73 expression in human breast cancer. A, Box plot showing the expression level of CD73 in breast cancer cell lines belonging to different breast cancer subtypes. B, Scatter plot showing the relative position of single cells from different breast cancer cell lines on a 2D luminal–basal and epithelial–mesenchymal plane. Individual cells are colored by CD73 expression levels, with red denoting a higher expression. C, A clustered heatmap showing top TFs that are correlated with CD73 expression in the CCLE breast cancer cell lines. D and E, MCF7RAS cells expressing doxycycline-controlled control Luciferase or SLUG and SOX9 coexpressing constructs were treated with doxycycline for 4 days to induce EMP. D, Phase-contrast images and Western blots for the indicated markers. Data represent four independent experiments. E, Bar graph representing percentage of cells expressing CD73. Data represent the SEM, two-tailed unpaired t test, **, P < 0.01. F, Boxplot showing Hallmark EMT AUCell score and CD73 expression of MCF7 cells treated with TGFß followed by the removal of the same over a total period of 10 days. Student t test was performed to assess the significance of difference of means in expression between day 0 with day 7 and day 7 with day 10 (third day of TGFß removal) *, P < 0.05. G, Barplot showing the percentage of cells in which nonzero counts of reads were detected from scRNA-seq of human breast cancer–derived cells from different breast cancer subtypes. H, Barplot showing the percentage of cells with nonzero counts of reads that were detected in tumor cells belonging to different breast cancer subtypes from human breast cancer samples. I, Scatterplot showing the relative positions of tumor cells from human breast cancer samples on a 2D luminal–basal and epithelial–mesenchymal plane. Individual cells are colored by CD73 expression levels with red denoting a higher expression.

  • Open Access

    Figure 2 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    CD8+ T cells are partially important for sensitizing qM tumors lacking CD73 to anti-CTLA4 ICB. A, Schema and tumor kinetics for sgCD73 tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–4 for each group. B, Representative immunofluorescence images of primary tumor sections obtained from (A) stained for CD4 (red) and DAPI (blue) at 63× magnification. Bar graph on the right represents quantification of CD4+ T cells in each high-power field (HPF) at 63× magnification for the indicated treatment groups. Fields of view (3–5) from the tumor interior were obtained for each tumor. Data represent three independent experiments, with n = 3–5 mice in each group. C, Schema and tumor kinetics for sgCD73 tumors propagated in WT or CD8-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–4 for each group. D, Schema and tumor kinetics for sgCD73 tumors propagated in WT or B2M-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–5 for each group. E, Representative immunofluorescence images of primary tumor sections obtained from (C) stained for CD4 (red) and DAPI (blue) at 63× magnification. Bar graph on the right represents quantification of CD4+ T cells in each HPF at 63× magnification for the indicated treatment groups. Fields of view (3–5) from the tumor interior were obtained for each tumor. Data represent three independent experiments, with n = 3–5 mice in each group. F, Representative immunofluorescence images of primary tumor sections obtained from (D) stained for CD4 (red) and DAPI (blue) at 63× magnification. Bar graph on the right represents quantification of CD4+ T cells in each HPF at 63× magnification for the indicated treatment groups. Fields of view (3–5) from the tumor interior were obtained for each tumor. Data represent three independent experiments, with n = 3–5 mice in each group. G, Schema and tumor kinetics for SnailHI qM tumor-bearing mice treated with the indicated antibodies. Data represent two independent experiments in which n = 3–4 for each group. H, Representative immunofluorescence images of primary tumor sections obtained from (G) stained for CD4 (red) and DAPI (blue) at 63× magnification. Bar graph on the right represents quantification of CD4+ T cells in each HPF at 63× magnification for the indicated treatment groups. Fields of view (3–5) from the tumor interior were obtained for each tumor. Data represent three independent experiments, with n = 3–5 mice in each group. A, C, D, and G, Data represent the SEM, two-way ANOVA, **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. B, E, F, and H, Bar graph data represent the SEM, two-tailed unpaired t test, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Scale bars are 100 μm.

  • Open Access

    Data from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    Although immune checkpoint blockade (ICB) therapy has generated dramatic responses in certain cancer types, breast tumors are largely unresponsive. Epithelial–mesenchymal plasticity (EMP) leads to the assembly of an immunosuppressive tumor microenvironment and drives resistance of breast tumors to immunotherapies. Importantly, targeting CD73 completely sensitizes quasi-mesenchymal (qM) breast tumors to anti-CTLA4 ICB therapy. However, the mechanism(s) of sensitization remained unknown. We demonstrate that targeting CD73 in qM breast tumors sensitizes them to anti-CTLA4 ICB therapy in a CD4+ T cell–dependent manner. Moreover, EMP results in elevated expression of cancer cell–intrinsic CD73 in human triple-negative breast cancers. Given the ability of qM cancer cells to metastasize and resist multiple therapies, these findings can instruct the formation of translational strategies for the treatment of human breast cancers. These findings also bring to the forefront the attractive possibility of utilizing the phenotypic plasticity of cancer cells along with CD73 and CD4+ T cells as a predictive criterion for immunotherapy responsiveness.Significance:EMP enables metastasis and drives resistance to multiple treatment regimens. Our work underscores the possibility of utilizing CD4+ T cells, CD73, and cancer plasticity as predictive criteria for responsiveness to immunotherapy.

  • Open Access

    Figure 3 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    CD4+ T cells drive sensitization of qM tumors lacking CD73 to anti-CTLA4 ICB. A, Schema and tumor kinetics for sgCD73 tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. B, Schema and tumor kinetics for sgCD73 tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. C, Schema and tumor kinetics for sgCD73 tumors propagated in WT or MHC-II-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. D, Schema and tumor kinetics for SnailHI qM tumor-bearing mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. E, Schema and tumor kinetics for SnailHI qM tumors propagated in WT or CD4-KO mice treated with the indicated antibodies. Data represent three independent experiments in which n = 3–7 for each group. F–I, Flow cytometry analysis for (F and H) IFNγ and (G and I) T-BET expression on CD4+ T cells as determined by flow cytometry from SnailHI qM control or sgCD73 tumor-bearing mice treated with the indicated antibodies. Tumors were harvested at 2 weeks (F and G) or 4 weeks (H and I) after treatment. Data represent three independent experiments in which n = 3–8 for each group. A–E, Data represent the SEM, two-way ANOVA, **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. F–I, Data represent the SEM, two-way ANOVA, with Tukey's multiple comparisons test *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

  • Open Access

    Figure 5 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    CD73 expression correlates with EMP in other murine models. scRNA-seq UMAP visualizations of untreated and 7-day immunotherapy-treated breast cancer samples from Hollern and colleagues. A, UMAP projection showing cell distribution colored by sample condition (treated vs. untreated). B, UMAP projection colored by Leiden cluster assignments. See also Supplementary Table S2. C–H, Feature plots displaying the normalized expression or signature scores across the UMAP space for (C) Epcam, (D) pEMT signature, (E) Cd8a, (F) Cd4, (G) Foxp3, and (H) Nt5e.

  • Open Access

    Figure 1 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    Presence of T cells in responding tumors. A, UMAP plot of unbiased clustering of SnailHI qM and sgCD73 tumors, in which each color-coded cluster represents a specific cell type or state. B, Genes representing each cluster depicted in the UMAP plot in A. See additional details in Supplementary Table S1. C, Bar plot showing the number of cells per cluster assigned to SnailHI qM control or sgCD73 conditions. D, Hashtag antibody-derived tag violin plots for the indicated clusters in SnailHI qM control or sgCD73 conditions. E, Immunofluorescence analysis of primary tumor sections obtained from SnailHI qM or sgCD73 tumor-bearing mice receiving control or anti-CTLA4 antibodies stained for CD4 (red), CD8 (white), and DAPI (blue) at 63× magnification. F, Quantification of CD8+ T cells and CD4+ T cells in each high-power field (HPF) at 63× magnification from E. Data represent three independent experiments, with n = 3–5 mice in each group. Fields of view (3–5) from each tumor interior were obtained for each group at 63× magnification. G, Immunofluorescence analysis of primary tumor sections obtained from SnailHI qM tumor-bearing mice receiving control, anti-CD73, anti-CTLA4, or combinations of anti-CD73 and anti-CTLA4 antibodies stained for CD4 (red), CD8 (white), and DAPI (blue) at 63× magnification. H, Quantification of CD8+ T cells and CD4+ T cells in each HPF at 63× magnification from G. Data represent three independent experiments, with n = 3–5 mice in each group. Fields of view (3–5) from each tumor interior were obtained for each group at 63× magnification. F and H, Data represent the SEM, two-tailed unpaired t test, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

  • Open Access

    Supplementary Table 2 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    Supplementary Table 2. Genes present in each cluster depicted in Figure 5B

  • Open Access

    Supplementary Figure S5 from CD4+ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy

    by Shiney Chandraganti, Caitlyn Sams, Sarthak Sahoo, Brian Feng, Isabel O’COnnell, Lynna Li, Sunita Nepal, Siddhartha Pulukuri, Kimaya Bakhle, Prathapan Thiru, et al.

    Supplementary Figure S5. Activation and exhaustion markers on CD4+ T-cell subsets present in responders and non-responders.